



NEWS RELEASE

## bridgebio pharma to participate in november investor events

2022-11-09

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:

- Jefferies Health Care Conference, London, UK: November 15<sup>th</sup> at 9:40 am ET
- Evercore ISI HealthCONx Conference, Virtual: November 30<sup>th</sup> at 10:05 am ET

To access the live webcast of BridgeBio's presentations, please visit the "Events" page within the Investors section of the BridgeBio website at <http://investor.bridgebio.com>. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit [bridgebio.com](http://bridgebio.com) and follow us on [LinkedIn](#) and [Twitter](#).

BridgeBio Contact:

Vikram Bali

**contact@bridgebio.com**

(650)-789-8220